Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPAZ: Tosedostat extension in elderly AML
NCT01180426Phase 2Unknown
- Sponsor
- Chroma Therapeutics
- Start
- Jun 2010
- Primary completion
- Jun 2013
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tosedostat in acute myeloid leukemia (AML), sponsored by Chroma Therapeutics. Status: unknown.
02
Drugs
tosedostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01180426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01180426.